Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
This article was originally published in PharmAsia News
Executive Summary
Takeda announced June 27 that U.S. FDA had denied approval of its type 2 diabetes agent alogliptin, a potential blockbuster poised to compete with similar molecules from Merck and the team of Bristol-Myers Squibb and AstraZeneca. The setback will delay alogliptin's launch by at least three years - and possibly longer - depending on the additional studies required by regulators
You may also be interested in...
A Closer Look: Alogliptin's Delay Accelerated Takeda's Pursuit Of Nycomed
Takeda found itself desperate to fill gaps with Actos LOE looming and alogliptin faltering, hastening a 10-year conversation with Nycomed.
A Closer Look: Alogliptin's Delay Accelerated Takeda's Pursuit Of Nycomed
Takeda found itself desperate to fill gaps with Actos LOE looming and alogliptin faltering, hastening a 10-year conversation with Nycomed.
Takeda And Pfizer Sign A Co-Promotion Deal To Market Actos In China
Facing a looming patent cliff, Japan's Takeda made good on a pledge to dive into emerging markets by signing a co-promotion deal with Pfizer to market its type 2 Actos diabetes drug in China